Locoregional treatments for triple-negative breast cancer

Annals of Oncology

Volumn 23, Issue SUPPL. 6, 2012, Pages

  Eiermann, W ^a   Vallis, K A ^b  

^a Interdisciplinary Oncology Center (IOZ)   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Locoregional; Radiation; Surgery; Treatment; Triple negative breast cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; EVEROLIMUS; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR;

ARTICLE; BASAL LIKE BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; DNA MICROARRAY; HUMAN; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 84867134511     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds192     Document Type: Article

References (40)

1. Cleere DW. Triple-negative breast cancer: a clinical update. Community Oncol 2011; 7: 203-211.
2. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast 2010; 19: 312-321.
3. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2010; 15 (Suppl. 5): 39-48.
4. Voduc KD, Cheang MC, Tyldesley S et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684-1691.
5. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
6. Wang SL, Li YX, Song YW et al. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiat Oncol Biol Phys 2011; 80: 1095-1101.
7. Aebi S, Davidson T, Gruber G et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v9-v14.
8. Cardoso F, Senkus-Konefka E, Fallowfield L et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice and guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v15-v19.
9. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer v2. 2011. Available at: http://www.nccn.org/professionals/physician_gls/breast.pdf (21 August 2012, date last accessed).
10. Halsted WS, I. A clinical and histological study of certain adenocarcinomata of the breast: and a brief consideration of the supraclavicular operation and of the results of operations for cancer of the breast from 1889 to 1898 at the Johns Hopkins Hospital. Ann Surg 1898; 28: 557-576.
11. Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat 2011; 129: 675-689.
12. Vandromme MJ, Umphrey H, Krontiras H. Image-guided methods for biopsy of suspicious breast lesions. J Surg Oncol 2011; 103: 299-305.
13. Sabel MS. Surgical considerations in early-stage breast cancer: lessons learned and future directions. Semin Radiat Oncol 2011; 21: 10-19.
14. Medina-Franco H, Garcia-Alvarez MN, Rojas-Garcia P et al. Body image perception and quality of life in patients who underwent breast surgery. Am Surg 2010; 76: 1000-1005.
15. Veiga DF, Veiga-Filho J, Ribeiro LM et al. Quality-of-life and self-esteem outcomes after oncoplastic breast-conserving surgery. Plast Reconstr Surg 2010; 125: 811-817.
16. Mickiewics E, Alvarez A, Di Pretorio M et al. Psychosocial sequelae in breast cancer patients: mastectomy (M) versus conservative surgery (CS). Eur J Cancer 1995; 31: S63.
17. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010; 12 (Suppl. 2): S3.
18. Bayraktar S, Gutierrez-Barrera AM, Liu D et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 2011; 130: 145-153.
19. Gonzalez-Angulo AM, Timms KM, Liu S et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17: 1082-1089.
20. Parker CC, Ampil F, Burton G et al. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? Surgery 2010; 148: 386-391.
21. Millar EK, Graham PH, O'Toole SA et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009; 27: 4701-4708.
22. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-5657.
23. Freedman GM, Anderson PR, Li T et al. Locoregional recurrence of triplenegative breast cancer after breast-conserving surgery and radiation. Cancer 2009; 115: 946-951.
24. Panoff JE, Hurley J, Takita C et al. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and postmastectomy radiation. Breast Cancer Res Treat 2011; 128: 899-906.
25. Nguyen PL, Taghian AG, Katz MS et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26: 2373-2378.
26. Solin LJ, Hwang WT, Vapiwala N. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. Clin Breast Cancer 2009; 9: 96-100.
27. Cody HS, III. Current surgical management of breast cancer. Curr Opin Obstet Gynecol 2002; 14: 45-52.
28. Fisher B, Costantino J, Redmond C et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328: 1581-1586.
29. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-1241.
30. Dragun AE, Pan J, Rai SN et al. Locoregional recurrence in patients with triplenegative breast cancer: preliminary results of a single institution study. Am J Clin Oncol 2010; 34: 231-237.
31. Julian TB, Costantino JP, Vicini FA et al. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. J Clin Oncol 2011; 29: 15s: Abstr 1011.
32. Gabos Z, Thoms J, Ghosh S et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat 2010; 124: 187-194.
33. Abdulkarim BS, Cuartero J, Hanson J et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011; 29: 2852-2858.
34. Jagsi R, Raad RA, Goldberg S et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys 2005; 62: 1035-1039.
35. Truong PT, Lesperance M, Culhaci A et al. Patient subsets with T1-T2, nodenegative breast cancer at high locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys 2005; 62: 175-182.
36. Kyndi M, Sorensen FB, Knudsen H et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 1419-1426.
37. Montagna E, Bagnardi V, Rotmensz N et al. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol 2012; 23: 324-331.
38. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
39. Albert JM, Kim KW, Cao C et al. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006; 5: 1183-1189.
40. Santillan AA, Kiluk JV, Cox JM et al. Outcomes of locoregional recurrence after surgical chest wall resection and reconstruction for breast cancer. Ann Surg Oncol 2008; 15: 1322-1329